In subgroup analysis, we found that patients with ER cancer diagnosed as breast cancer, with metastasis, thyroid cancer patients with multiple tumors or I131 therapy, breast cancer patients diagnosed as HER2+ or TNBC genotype or treated with chemotherapy showed a remarkably lower actMBCs and higher intMBCs or atyMBCs (Figures 3-5, 7, 8; Supplementary Figure 2). This evidence concerns the gene ERBB2 and breast carcinoma.